ArticleGels (Basel, Switzerland)2026
Bioinspired Cross-Linked Anionic Hydrogel Microparticles as Potential Adjuvants for Safe Vaccines: Colloidal-Chemical Characteristics, Morphology and Biological Properties.
Article in Gels (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Novel anionic cross-linked hydrogel-based microparticles with controlled size, functionality, porosity, and morphology were synthesized via tailored precipitation polymerization of hydrophobic and hydrophilic monomers in the presence of dimethacrylate as a cross-linking agent. The resulting hydrogel microparticles (HG5), with a size of 250 ± 50 nm and a polydispersity index of 0.079, were readily dispersible in water and formed stable suspensions at physiological pH (7.2-7.4). Their physicochemical properties were comprehensively characterized using FT-IR, NMR, DLS, SAXS, TEM, and turbidimetry. HG5 efficiently incorporated albumin as a model antigen with a loading efficiency of 95%, forming stable hydrogel-protein complexes that maintained their hydrodynamic size and colloidal stability over one month of storage. Biological evaluation demonstrated low toxicity toward pseudonormal cell lines, with cell viability remaining above 50% at concentrations up to 5 mg/mL and no detectable apoptotic effects in HEK293 cells. Human peripheral blood mononuclear cells (PBMCs) were sensitive to HG5 exposure, exhibiting an IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.